PRESS RELEASE
REGULATED INFORMATION
23 May 2024, 06:00 pm CEST
Ghent, Belgium - 23 May 2024 - Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that all proposed resolutions submitted to the Annual and Extraordinary General Meetings of Shareholders were approved at the meetings held today at 09:00 am CEST.
The items on the agendas of the meetings included (among other) the approval of a number of resolutions relating to the financial year ended 31 December 2023,
the approval of the revised remuneration policy, the reappointment of the statutory auditor, certain approvals in accordance with Article 7:151 of the Belgian Companies and Associations Code, the approval of the contribution in kind of certain receivables pursuant to the unsecured and subordinated convertible loan agreement entered into on 7 February 2024 between the Company and Partners in Equity and Rosetta Capital in the principal amount of EUR 3,041,507.59, as well as the renewal of the authorization to the Board of Directors to increase the share capital within the framework of the authorised capital.
The minutes of the shareholders' meetings, as well as the revised versions of the Company's articles of
association, can be accessed on the Company's website (https://www.sequanamedical.com/investors/shareholder-information/).
For more information, please contact:
Sequana Medical
Ian Crosbie
Chief Executive Officer
E: IR@sequanamedical.com (mailto:IR@sequanamedical.com)
T: +44 7973 42 99 17
About Sequana Medical
Sequana Medical NV is a pioneer in treating fluid overload, a serious and frequent clinical complication in patients with liver disease, heart failure and
cancer. This causes major medical issues including increased mortality, repeated
hospitalizations, severe pain, difficulty breathing and restricted mobility. Although diuretics are standard of care, they become ineffective, intolerable or
exacerbate the problem in many patients. There are limited effective treatment options, resulting in poor clinical outcomes, high costs and a major impact on their quality of life. Sequana Medical is seeking to provide innovative treatment options for this large and growing "diuretic-resistant" patient population.
alfapump® and DSR® are Sequana Medical's proprietary platforms that work with the body to treat diuretic-resistant fluid overload, delivering major clinical and quality of life benefits for patients and reducing costs for healthcare systems.
The Company's Premarket Approval (PMA) application for the alfapump was submitted to the US FDA in December 2023 and accepted for substantive review in January 2024, having reported positive primary and secondary endpoint data from the North American pivotal POSEIDON study in recurrent or refractory ascites due
to liver cirrhosis. US market approval of the alfapump is anticipated before the end of Q1 2025 with US commercial launch planned for H2 2025.
Results of the Company's RED DESERT and SAHARA proof-of-concept studies in heart
failure support DSR's mechanism of action as breaking the vicious cycle of cardiorenal syndrome. All three patients from the non-randomized cohort of MOJAVE, a US randomized controlled multi-center Phase 1/2a clinical study, have been successfully treated with DSR, resulting in a dramatic improvement in diuretic response and virtual elimination of loop diuretic requirements. The independent Data Safety Monitoring Board approved the start of the randomized MOJAVE cohort of up to a further 30 patients, which is planned after alfapump US
PMA approval.
Sequana Medical is listed on the regulated market of Euronext Brussels (Ticker: SEQUA.BR) and headquartered in Ghent, Belgium. For further information, please visit www.sequanamedical.com (http://www.sequanamedical.com).
Important Regulatory Disclaimers
The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump system is currently under clinical
investigation (POSEIDON Trial) and is being studied in adult patients with refractory or recurrent ascites due to liver cirrhosis. DSR® therapy is still in
development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between DSR therapy and ongoing investigations with the alfapump system in Europe, the United States or Canada.
Note: alfapump® and DSR® are registered trademarks.
Forward-looking statements
This press release may contain predictions, estimates or other information that might be considered forward-looking statements. Such forward-looking statements are not guarantees of future performance. These forward-looking statements represent the current judgment of Sequana Medical on what the future holds, and are subject to risks and uncertainties that could cause actual results to differ
materially. Sequana Medical expressly disclaims any obligation or undertaking to
release any updates or revisions to any forward-looking statements in this press
release, except if specifically required to do so by law or regulation. You should not place undue reliance on forward-looking statements, which reflect the
opinions of Sequana Medical only as of the date of this press release.
Â